- •Costs for treating multiple sclerosis decreased by 0.4% per patient after the introduction of 2011 diagnostic criteria.
- •The highest slope change in annual costs per patient was in 2015 (10%), after the introduction of Alemtuzumab.
- •Disease modifying treatments remain the main responsible for increased medical direct costs in multiple sclerosis.
- •Improved diagnostic skills and patient profiling can mitigate costs for treating multiple sclerosis at patient level.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Agenzia Italiana del Farmaco, 2019. Banca Dati Farmaci dell'AIFA [WWW Document]. URLhttps://www.farmaci.agenziafarmaco.gov.it/(accessed 9.18.19).
Bank of Italy, n.d. Euro foreign exchange reference rates as of 5 Apr 2019 [WWW Document]. URLhttps://www.bancaditalia.it/compiti/operazioni-cambi/cambio/cambi_rif_20190405/(accessed 4.5.19).
- Quasi-experimental study designs series—paper 4: uses and value.J. Clin. Epidemiol. 2017; 89: 21-29https://doi.org/10.1016/j.jclinepi.2017.03.012
- New insights into the burden and costs of multiple sclerosis in Europe: Results for italy.Mult. Scler. 2017; 23: 104-116https://doi.org/10.1177/1352458517708125
- Interrupted time series regression for the evaluation of public health interventions: a tutorial.Int. J. Epidemiol. 2017; 46: 348-355https://doi.org/10.1093/ije/dyw098
- The direct cost of patients with multiple sclerosis: a survey from Italian Ms centres.Neurol. Sci. 2011; 32: 1035-1041https://doi.org/10.1007/s10072-011-0578-4
- Cost of disease-modifying therapies for multiple sclerosis.Neurology. 2015; 84: e181-e185https://doi.org/10.1212/WNL.0000000000001676
- Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria.J. Neurol. Neurosurg. Psychiatry. 2015; 86: 584-585https://doi.org/10.1136/jnnp-2014-308675
- Use (and misuse) of the McDonald criteria to diagnose multiple sclerosis.Eur. J. Neurol. 2018; 25: 209-210https://doi.org/10.1111/ene.13501
- Diagnosis of multiple sclerosis: progress and challenges.Lancet. 2017; 389: 1336-1346https://doi.org/10.1016/S0140-6736(16)30959-X
- Fatigue in multiple sclerosis: the role of thalamus.Mult. Scler. 2019; (1352458519851247)https://doi.org/10.1177/1352458519851247
- Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?.J. Neurol. Neurosurg. Psychiatry. 2018; 89: 844-850https://doi.org/10.1136/jnnp-2017-317509
- Early versus later treatment start in multiple sclerosis: a register-based cohort study.Eur. J. Neurol. 2018; 25: 1262-e110https://doi.org/10.1111/ene.13692
- MRI only conversion to multiple sclerosis following a clinically isolated syndrome.J. Neurol. Neurosurg. Psychiatry. 2011; 82: 176-179https://doi.org/10.1136/jnnp.2010.208660
- The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses.Front. Neurol. 2019; 10101374https://doi.org/10.3389/fneur.2018.01150
- Cost of illness of multiple sclerosis - A Systematic review.PLoS ONE. 2016; 11e0159129https://doi.org/10.1371/journal.pone.0159129
European Medicine Agency, EMA, 2019. European public assessment reports. [WWW Document]. URLhttps://www.ema.europa.eu/en/medicines(accessed 9.18.19).
- Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 Magnims and 2010 McDonald criteria: a retrospective study.Lancet Neurol. 2018; 17: 133-142https://doi.org/10.1016/S1474-4422(17)30469-6
- Is it time to target no evident disease activity (NEDA) in multiple sclerosis?.Mult. Scler. Relat. Disord. 2015; 4: 329-333https://doi.org/10.1016/j.msard.2015.04.006
- Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden.Mult. Scler. J. - Exp. Transl. Clin. 2019; 5205521731985838https://doi.org/10.1177/2055217319858383
- Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: a magnims multicentre study.Mult. Scler. J. 2019; 25: 352-360https://doi.org/10.1177/1352458517751647
- Economics and cost-effectiveness of multiple sclerosis therapies in the USA.Neurotherapeutics. 2017; 14: 1018-1026https://doi.org/10.1007/s13311-017-0566-3
- The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?.Neurology. 2015; 84: 2185-2192https://doi.org/10.1212/WNL.0000000000001608
- Modeling approaches in cost-effectiveness analysis of disease-modifying therapies for relapsing-remitting multiple sclerosis: an updated systematic review and recommendations for future economic evaluations.Pharmacoeconomics. 2018; 36: 1223-1252https://doi.org/10.1007/s40273-018-0683-9
- Disease-Modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies.Pharmacoeconomics. 2018; 36: 189-204https://doi.org/10.1007/s40273-017-0577-2
- Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.Brain. 2017; 140: 1426-2443https://doi.org/10.1093/brain/awx185
- Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands.J. Med. Econ. 2013; 16: 939-950https://doi.org/10.3111/13696998.2013.807267
- New insights into the burden and costs of multiple sclerosis in Europe.Mult. Scler. 2017; 23: 1123-1136https://doi.org/10.1177/1352458517694432
- Promoting remyelination in multiple sclerosis: current drugs and future prospects.Mult. Scler. 2015; 21: 541-549https://doi.org/10.1177/1352458514566419
- Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing–remitting multiple sclerosis.Eur. J. Neurol. 2019; 26: 540-545https://doi.org/10.1111/ene.13853
- US senate committee launches investigation into drug pricing.BMJ. 2015; 351: h5989https://doi.org/10.1136/bmj.h5989
- Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.Ann. Neurol. 2001; 50: 121-127
- Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs.Clin. Outcomes Res. 2015; : 575-581https://doi.org/10.2147/CEOR.S88531
- A 8-year retrospective cohort study comparing interferon-β formulations for relapsing‐remitting multiple sclerosis.Mult. Scler. Relat. Disord. 2018; 19https://doi.org/10.1016/j.msard.2017.11.006
- Healthcare costs for treating relapsing multiple sclerosis and the risk of progression: a retrospective italian cohort study from 2001 to 2015.PLoS ONE. 2017; 12e0169489https://doi.org/10.1371/journal.pone.0169489
- Predictors of the 10-year direct costs for treating multiple sclerosis.Acta Neurol. Scand. 2017; 135: 522-528https://doi.org/10.1111/ane.12630
- Healthcare resource utilization and costs for multiple sclerosis management in the campania region of italy: comparison between centre-based and local service healthcare delivery.PLoS ONE. 2019; 14e0222012https://doi.org/10.1371/journal.pone.0222012
- Economic burden of multiple sclerosis: a systematic review of the literature.Pharmacoeconomics. 2010; 28: 363-379https://doi.org/10.2165/11532230-000000000-00000
- The great recession and increased cost sharing in European health systems.Health Aff. 2016; 35: 1204-1213https://doi.org/10.1377/hlthaff.2015.1170
- Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.Ann. Neurol. 2011; 69: 292-302https://doi.org/10.1002/ana.22366
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria.Ann. Neurol. 2005; 58: 840-846https://doi.org/10.1002/ana.20703
- Economic impact of multiple sclerosis in italy: focus on rehabilitation costs.Neurol. Sci. 2015; 36: 227-234https://doi.org/10.1007/s10072-014-1925-z
- Burden and cost of neurological diseases: a European north-south comparison.Acta Neurol. Scand. 2014; : 1-7https://doi.org/10.1111/ane.12339
- Quasi-experimental study designs series—paper 5: a checklist for classifying studies evaluating the effects on health interventions—a taxonomy without labels.J. Clin. Epidemiol. 2017; 89: 30-42https://doi.org/10.1016/j.jclinepi.2017.02.016
- Investigating the generalizability of economic evaluations conducted in Italy: a critical review.Value Heal. 2015; 18: 709-720https://doi.org/10.1016/j.jval.2015.03.1795
- The multiple sclerosis care unit.Mult. Scler. 2018; https://doi.org/10.1177/1352458518807082
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173https://doi.org/10.1016/S1474-4422(17)30470-2
- Multiple sclerosis.Lancet. 2018; 391: 1622-1636https://doi.org/10.1016/S0140-6736(18)30481-1
- Treatment decisions in multiple sclerosis - insights from real-world observational studies.Nat. Rev. Neurol. 2017; 13: 105-118https://doi.org/10.1038/nrneurol.2016.188
- Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.Mayo Clin. Proc. 2014; 89: 225-240https://doi.org/10.1016/j.mayocp.2013.11.002
- Disease-Modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: a cost-utility analysis.CNS Drugs. 2018; 32: 1145-1157https://doi.org/10.1007/s40263-018-0566-9